Cyxone AB announces last day of trading in BTA
Cyxone AB’s ("Cyxone" or the "Company") rights issue, with a subscription period ending on 15 August 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is 29 August 2024, and the stop day is 2 September 2024.
In August 2024, Cyxone carried out a rights issue which provided the Company with approximately SEK 6.4 million before issue costs. The previously communicated outcome was lacking a subscription of SEK 67,419.20 and this subscription has thus been added to the numbers below. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in BTA is 29 August 2024 and the cut-off date is 2 September 2024. Shares are expected to be distributed to the VP account/depot on 4 September 2024.
After the Swedish Companies Registration Office's registration of the rights issue, the total number of shares in the Company amounts to 375,057,779 shares and the share capital amounts to SEK 15,002,311.16.
Advisors
In connection with the Rights Issue, Sedermera Corporate Finance AB assists the Company with project management, Markets & Corporate Law Nordic AB with legal advice and Hagberg & Aneborn Fondkommission AB with issuing services.
For more information about the Rights Issue, please contact:
Sedermera Corporate Finance AB
Phone: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
www.sedermera.se
For more information about the Company, please contact:
Kjell Stenberg, CEO
Phone: +46 (0)70 781 88 08
E-mail: kjell.g.stenberg@cyxone.com
www.cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com
Tags: